首页> 外文期刊>Perfusion >Custodiol cardioplegia solution compared to cold blood cardioplegia in pediatric cardiac surgery: a single-institution experience
【24h】

Custodiol cardioplegia solution compared to cold blood cardioplegia in pediatric cardiac surgery: a single-institution experience

机译:Custodiol cardiplegia解决方案与儿科心脏手术的冷血心液相比:单一机构经验

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: Custodiol is an intracellular, crystalloid cardioplegia solution that is a single-dose alternative to multi-dose cold blood cardioplegia; however, there is scarce data regarding its use in infants and children. The objective of this study was to compare its impact on myocardial function in infants. Methods: Single-center retrospective review including 132 patients Results: Patients receiving Custodiol were slightly younger (100 +/- 62 days) and lower weight (4.7 +/- 1.3 kg) compared to 152 +/- 86 days and 5.2 +/- 1.3 kg for blood cardioplegia (p < 0.05). The Society of Thoracic Surgeons/European Association for Cardio-Thoracic Surgery Congenital Heart Surgery score was similar between both groups. Average cardiopulmonary bypass time was similar between both groups (Custodiol 93 +/- 54 minutes vs. blood 81 +/- 44 minutes, p = 0.46) as was aortic cross-clamp time (Custodiol 58 +/- 33 minutes vs. cold blood 53 +/- 33 minutes, p = 0.62). Pre-operative left ventricular ejection fraction was similar for blood 73 +/- 8% versus Custodiol 70 +/- 9%, p = 0.21. There was also no intergroup difference in left ventricular ejection fraction 24 hours post op (blood 64 +/- 9% vs. Custodiol 65 +/- 12%, p = 0.53) or at discharge (blood 66 +/- 10% vs. Custodiol 66 +/- 11%, p = 0.95). The pre-operative right ventricle function by fractional area change was also similar in blood cardioplegia (46 +/- 13%) versus Custodiol (48 +/- 9%, p = 0.38) and showed similar drops in parameters in the two groups 24 hours after surgery and at discharge. Conclusion: Single-dose Custodiol is as safe as blood cardioplegia for myocardial protection in congenital cardiac surgery for the cross-clamp times evaluated in this study. Evaluation at longer cross-clamp times would be helpful to determine if there is a greater benefit to single-dose Custodiol versus more repeated doses of blood cardioplegia for longer cross-clamp times.
机译:目的:Custodiol是一种细胞内,晶体心脏瘫溶液,是一种单剂量替代的多剂量冷血液软血分咽;但是,有关其在婴儿和儿童的使用稀缺数据。本研究的目的是比较其对婴儿心肌功能的影响。方法:单中心回顾性评论,包括132名患者的结果:接受保留醇的患者稍微小(100 +/- 62天),重量较低(4.7 +/- 1.3千克),而152 +/- 86天和5.2 +/- 1.3公斤血液心肺血瘀(P <0.05)。两组之间的胸外科医生/欧洲心动外科手术协会和欧洲心动手术协会相似。两组之间的平均心肺旁路时间(Custodiol 93 +/- 54分钟与血液81 +/- 44分钟,P = 0.46)与主动脉交叉钳位时间(Cortodiol 58 +/- 33分钟与冷血53 +/- 33分钟,p = 0.62)。术前左心室喷射分数对于血液相似73 +/- 8%,与金属醇70 +/- 9%,p = 0.21。左心室喷射分数没有24小时后差异差异(血液64 +/- 9%Vs. Custodiol 65 +/- 12%,p = 0.53)或放电(血液66 +/- 10%与Custodiol 66 +/- 11%,p = 0.95)。血液心脏血晕(46 +/- 13%)与Custodiol(48 +/- 9%,P = 0.38)中的术前右心室变化也相似,并且在两组中显示出类似的参数下降手术后的小时和放电。结论:单剂量保留醇与血液心脏病一样安全,用于本研究中评估的交叉钳位时的先天性心脏手术中的心肌保护。在较长的交叉钳位时评估将有助于确定对单剂量保管的更大益处,对于更长的交叉夹持时,单剂量保留醇对更重复剂量的血液心血管。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号